Edition:
India

Corbus Pharmaceuticals Holdings Inc (CRBP.OQ)

CRBP.OQ on NASDAQ Stock Exchange Global Market

4.99USD
18 Oct 2019
Change (% chg)

$0.06 (+1.22%)
Prev Close
$4.93
Open
$4.90
Day's High
$4.99
Day's Low
$4.79
Volume
168,401
Avg. Vol
180,125
52-wk High
$9.11
52-wk Low
$4.45

Latest Key Developments (Source: Significant Developments)

Corbus Pharmaceuticals Q2 Earnings Per Share $0.03
Thursday, 8 Aug 2019 

Aug 8 (Reuters) - Corbus Pharmaceuticals Holdings Inc ::CORBUS PHARMACEUTICALS REPORTS 2019 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CLINICAL AND CORPORATE UPDATES.Q2 EARNINGS PER SHARE $0.03.Q2 EARNINGS PER SHARE ESTIMATE $-0.36 -- REFINITIV IBES DATA.CRB-4001 ON COURSE TO START PHASE 1 STUDY IN 2019 AS A CANDIDATE FOR NASH.  Full Article

Corbus Pharmaceuticals Announces Public Offering Of 5.39 mln Common Shares At $6.50 per share
Friday, 25 Jan 2019 

Jan 25 (Reuters) - Corbus Pharmaceuticals Holdings Inc ::CORBUS PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 5.39 MILLION COMMON SHARES PRICED AT $6.50PER SHARE.  Full Article

Corbus Pharmaceuticals Announces Strategic Collaboration With Kaken Pharmaceutical
Thursday, 3 Jan 2019 

Jan 3 (Reuters) - Corbus Pharmaceuticals Holdings Inc ::CORBUS PHARMACEUTICALS ANNOUNCES STRATEGIC COLLABORATION WITH KAKEN PHARMACEUTICAL CO., LTD. TO DEVELOP AND COMMERCIALIZE LENABASUM IN JAPAN FOR SYSTEMIC SCLEROSIS AND DERMATOMYOSITIS.CORBUS PHARMACEUTICALS - KAKEN RECEIVES AN EXCLUSIVE LICENSE TO COMMERCIALIZE AND MARKET LENABASUM IN JAPAN FOR SYSTEMIC SCLEROSIS AND DERMATOMYOSITIS.CORBUS PHARMACEUTICALS HOLDINGS INC - KAKEN WILL MAKE AN UPFRONT PAYMENT TO CORBUS OF $27 MILLION.CORBUS PHARMACEUTICALS HOLDINGS INC - WILL BE ELIGIBLE TO RECEIVE IN ADDITION UP TO $173 MILLION UPON CERTAIN MILESTONE ACHIEVEMENTS.  Full Article

Corbus Pharmaceuticals Q3 Loss Per Share $0.26
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Corbus Pharmaceuticals Holdings Inc ::CORBUS PHARMACEUTICALS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q3 LOSS PER SHARE $0.26.Q3 EARNINGS PER SHARE VIEW $-0.22 -- THOMSON REUTERS I/B/E/S.CORBUS EXPECTS TO REPORT TOPLINE RESULTS FROM PHASE 3 RESOLVE-1 STUDY IN 2020.COMPANY ENDED Q3 WITH APPROXIMATELY $55.7 MILLION OF CASH AND CASH EQUIVALENTS..  Full Article

Corbus Pharmaceuticals Says Co Obligated To Pay Jenrin Potential Milestone Payments Of Up To $18.4 Mln For Each Compound Elects To Develop
Thursday, 20 Sep 2018 

Sept 20 (Reuters) - Corbus Pharmaceuticals Holdings Inc ::CORBUS PHARMACEUTICALS- CO OBLIGATED TO PAY JENRIN POTENTIAL MILESTONE PAYMENTS OF UP TO $18.4 MILLION FOR EACH COMPOUND ELECTS TO DEVELOP.CORBUS PHARMACEUTICALS SAYS CO OBLIGATED TO PAY JENRIN ROYALTIES IN MID, SINGLE DIGITS BASED ON NET SALES OF ANY LICENSED PRODUCTS - SEC FILING.CORBUS PHARMACEUTICALS-FOR 10 YRS FROM DEAL, JENRIN/AFFILIATES WILL NOT DEVELOP/COMMERCIALIZE COMPOUNDS INTENDED TO/DO, MODULATE CANNABINOID RECEPTOR.  Full Article

Corbus Pharmaceuticals Expands Target Indications By Adding Over 600 Compounds Focused On Endocannabinoid System From Jenrin Discovery
Thursday, 20 Sep 2018 

Sept 20 (Reuters) - Corbus Pharmaceuticals Holdings ::CORBUS PHARMACEUTICALS EXPANDS TARGET INDICATIONS BY ADDING OVER 600 COMPOUNDS FOCUSED ON ENDOCANNABINOID SYSTEM FROM JENRIN DISCOVERY LLC.CORBUS PHARMACEUTICALS SAYS TRANSACTION EXPECTED TO HAVE MINIMAL IMPACT ON CO'S CASH FLOW THROUGH END OF 2019.CORBUS PHARMACEUTICALS SAYS PIPELINE INCLUDES CRB-4001, A NOVEL CB-1 INVERSE AGONIST, SCHEDULED BY CO TO ENTER PHASE 1 STUDY IN 2019.CORBUS PHARMACEUTICALS SAYS DEAL FOR UP-FRONT CASH PAYMENT, MILESTONE PAYMENTS TO BE PAID ON ACHIEVEMENT OF SOME DEVELOPMENT & REGULATORY MILESTONES.CORBUS PHARMACEUTICALS - BELIEVES PIPELINE WILL SUPPORT ADVANCEMENT OF 1 TO 2 NEW DRUG CANDIDATES INTO CLINICAL TESTING EACH YEAR STARTING 2020.CORBUS PHARMACEUTICALS SAYS A PHASE 3 STUDY OF LENABASUM FOR TREATMENT OF DERMATOMYOSITIS PLANNED TO BEGIN END OF 2018.  Full Article

Corbus Pharmaceuticals Reports 2017 Financial Results And Provides Clinical Update
Monday, 12 Mar 2018 

March 12 (Reuters) - Corbus Pharmaceuticals Holdings Inc ::CORBUS PHARMACEUTICALS REPORTS 2017 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATE.CORBUS PHARMACEUTICALS HOLDINGS INC - CASH AND CASH EQUIVALENTS BALANCE AT DECEMBER 31, 2017 WAS APPROXIMATELY $62.5 MILLION.CORBUS PHARMACEUTICALS - EXPECTS CURRENT CASH ON HAND, EXPECTED MILESTONE PAYMENTS TO FUND OPERATIONS THROUGH Q4 OF 2019.  Full Article

Corbus Pharmaceuticals Files For Mixed Shelf Of Up To $200 Mln ‍​
Saturday, 6 Jan 2018 

Jan 5 (Reuters) - Corbus Pharmaceuticals Holdings Inc ::CORBUS PHARMACEUTICALS HOLDINGS INC FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING ‍​.  Full Article

Corbus Pharmaceuticals Q3 loss per share $0.14
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Corbus Pharmaceuticals Holdings Inc : :Corbus Pharmaceuticals reports 2017 third quarter financial results and highlights recent corporate and clinical advancements.Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.Q3 loss per share $0.14.Corbus Pharmaceuticals Holdings Inc - ‍company expects current cash on hand to fund operations into Q4 of 2019,based on current planned expenditures​.Corbus Pharmaceuticals Holdings Inc - qtrly revenue $796,312 versus $742,558.  Full Article

Corbus Pharma reports improvement in skin conditions in a mid-stage study
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Corbus Pharmaceuticals Holdings Inc :Corbus Pharmaceuticals reports significant improvement in mRSS and other clinical outcomes at 28-weeks in systemic sclerosis open-label extension of phase 2 study.Corbus Pharmaceuticals Holdings Inc - ‍Company on track to commence phase 3 study Q4 2017​.Corbus Pharmaceuticals Holdings Inc - Were no severe or serious adverse events and no clinically significant laboratory abnormalities related to drug​.Corbus Pharmaceuticals - "‍Our focus now is to ensure successful execution of our phase 3 study, and we are on track to commence this before year end"​.  Full Article